Dekristol

Quick links to important sections

Dekristol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dekristol

Property Description
Active ingredient Colecalciferol (Vitamin D3)
Form Oral liquid (drops), capsules, tablets
Pharmacological class Vitamin D analog, Nutritional supplement
Common use Maintaining calcium homeostasis
Origin Pro-hormone (Endogenous or derived)

What Type of Medicine is Dekristol (Colecalciferol)?

Dekristol is a medicine whose active substance is Colecalciferol, which is chemically and biologically identical to Vitamin D3. It functions as a mono preparation and is classified as a fat-soluble vitamin and a nutritional supplement. Within the pharmacological class of Vitamin D analogs, Colecalciferol is specifically defined as a pro-hormone because it is structurally a secosteroid that requires metabolic activation inside the body—in the liver and kidneys—before it becomes the fully active hormone, Calcitriol (1,25-dihydroxyvitamin D). This identity is clinically recognized for its role in regulating fundamental bone metabolism processes. This indicates that the medicine is crucial for supplementing a key biological process.


Composition, Origin, and Available Forms

The preparation is designed for oral administration, and its formulation often incorporates a fatty vehicle, such as medium-chain triglycerides, to ensure the optimal solubility and absorption of the fat-soluble Colecalciferol in the digestive tract. Colecalciferol is either produced endogenously in the skin upon sunlight exposure or derived from external sources for pharmaceutical compounding. As a unique feature, Dekristol is widely known for its availability in high-concentration capsules in certain markets, alongside oral drops and tablets, enabling varied dosing strategies for adults and infants.


What is the General Purpose of Taking Colecalciferol?

The overarching purpose of taking Colecalciferol is to provide the critical precursor molecule necessary to enable the maintenance of calcium homeostasis. The subsequent active hormone derived from Colecalciferol is essential for stimulating the intestines to effectively absorb dietary calcium and phosphate into the bloodstream. This physiological action facilitates the proper mineralization and structural integrity of the bones. Therefore, the general benefit of the medicine is supporting the proper mineralization and structural integrity of the bones. A typical use scenario involves long-term supplementation where natural production is insufficient, such as during winter months or for individuals with limited sun exposure.

Regulatory References

  1. calcium homeostasis
  2. MedlinePlus - NIH

What side effects are possible with Dekristol?

Possible Side Effects and Safety Information: Dekristol

This section outlines the officially documented safety profile of Dekristol, based strictly on government regulatory documents.

Safety Restrictions and Contraindications

Regulatory safety information is primarily structured by a critical limitation concerning an inactive ingredient. Dekristol is formally contraindicated (must not be used) in patients who have a known hypersensitivity or allergy to the active substance, Vitamin D, its metabolites, or any of the excipients, particularly arachis oil (peanut oil).

Documented Adverse Reactions

The most significant and serious safety concern documented relates directly to the presence of arachis oil. This excipient is an officially recognized allergen, which carries the potential risk of inducing severe allergic reactions.

Adverse Reaction Category Primary Safety Concern
Immune System Disorders Hypersensitivity, severe allergic reaction (anaphylaxis)

Structuring the Safety Profile

The safety profile is defined by the absolute necessity to screen for and exclude patients with specific pre-existing allergies. The presence of the excipient arachis oil dictates the most serious potential risk—a severe, potentially life-threatening allergic reaction (anaphylaxis). Therefore, the regulatory documentation emphasizes the contraindication to ensure patient selection strictly avoids individuals with known peanut or soya allergies, as this restriction is mandatory for risk mitigation.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Colecalciferol (Dekristol), also known as hypervitaminosis D, is defined by an accumulation of the substance that leads to hypercalcaemia—an abnormally high level of calcium in the blood. Overdose results from acute massive intake or prolonged excessive use.

Documented Manifestations The officially documented signs and symptoms are primarily consequences of this calcium imbalance. Manifestations may include gastrointestinal disturbances such as anorexia, nausea, and vomiting, alongside systemic symptoms like excessive thirst (polydipsia), frequent urination (polyuria), muscle weakness, fatigue, confusion, and bone pain.

Severe Outcomes and Required Action Severe or chronic hypercalcaemia documented in regulatory labeling can lead to serious complications. These life-threatening systemic outcomes include irreversible renal impairment (nephrocalcinosis), formation of kidney stones (renal calculi), and potentially cardiac arrhythmias. Because of this risk, immediate medical attention is required upon suspicion of overdose, especially if severe symptoms like collapse or profound confusion occur.

Management Protocol Regulatory documents state that management involves the immediate discontinuation of the medicine and any calcium supplements. No specific antidote is known for Colecalciferol toxicity; therefore, treatment is symptomatic and supportive, focused on correcting the hypercalcaemia through procedures like rehydration and the use of medications such as diuretics, calcitonin, or bisphosphonates. Continuous monitoring of serum electrolytes and renal function is mandated during treatment.

Therapeutic Uses of Dekristol

The primary role of Colecalciferol (Dekristol) is the treatment and prevention of Vitamin D deficiency, which plays a role in managing symptoms related to systemic imbalance. The medicine is used alongside calcium and may be part of symptomatic management to address their associated symptomatic burden.

The medication is commonly used to correct the underlying metabolic imbalance that is relevant in conditions where functional stability becomes affected, such as Osteomalacia in adults and Rickets in children. It is also applied in addressing chronic low levels and is relevant for easing symptoms linked to organ-specific functional stress. It is commonly used to help with conditions that present with systemic or localized discomfort, such as Vitamin D deficiency, Osteomalacia, Rickets, and Hypoparathyroidism.

The use of Colecalciferol supports the maintenance of skeletal structural integrity and helps address symptoms related to physical discomfort. The treatment assists in alleviating diffuse bone and muscle pain and is relevant for easing muscular weakness. The prophylactic use is relevant when supportive symptom management is appropriate in high-risk groups, such as breastfed infants, older adults, and those with malabsorption syndromes. This provides supportive relief when symptoms interfere with routine activities and contributes to easing the overall symptom load.

“The treatment assists in alleviating diffuse bone and muscle pain and is relevant for easing muscular weakness.”


Quick Fact: Relief for Musculoskeletal Discomfort Colecalciferol supports general well-being during symptomatic phases and may assist with managing symptoms that create noticeable physiological strain, particularly concerning bone and muscle health.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Population Eligibility for Dekristol (Colecalciferol)

Regulatory documents strictly define who can and cannot use Colecalciferol based primarily on the patient's existing calcium balance and kidney function. Use is contraindicated in several groups to prevent dangerous elevations of calcium levels.

Absolute Contraindications (Must Not Use)
Hypercalcaemia (high blood calcium)
Hypercalciuria (high urine calcium)
Hypervitaminosis D (excess Vitamin D)
Severe Renal Impairment or Nephrolithiasis (kidney stones)
Hypersensitivity to Colecalciferol or specific excipients like arachis oil in certain formulations

Eligibility for use requires caution in patients with conditions like Sarcoidosis or moderate renal impairment, necessitating close monitoring of calcium levels. Colecalciferol is generally permitted for Adults and Adolescents (over 12 years). High-dose capsules are not recommended for children under 12 years due to safety and formulation risks. During pregnancy and lactation, use is generally allowed but restricted to lower doses; high doses (over 4,000 IU daily) are officially not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Colecalciferol (Dekristol) is officially defined by substances that alter its exposure or create pharmacodynamic risk. Pharmacokinetic interactions involve medicines that may diminish the effect of Colecalciferol through hepatic enzyme induction, such as certain anti-convulsants (e.g., Phenytoin) and Rifampicin. Furthermore, agents like Isoniazid may reduce effectiveness by inhibiting the metabolic activation process itself. Drugs that impair fat absorption, including Cholestyramine and liquid paraffin, are documented to interfere with the uptake of this fat-soluble vitamin, resulting in reduced Colecalciferol exposure.

Documented Pharmacodynamic and Subtractive Interactions

Interaction Type Interacting Substance Categories Official Outcome Pattern
Increased Risk Thiazide diuretics (e.g., Benzothiadiazine derivatives) Increases the risk of hypercalcaemia due to decreased urinary calcium excretion.
Augmented Toxicity Cardiac Glycosides (e.g., Digitalis) Colecalciferol may augment their toxicity due to hypercalcaemia-induced cardiac arrhythmias.
Effect Reduction Glucocorticoids Concomitant use can decrease the effect of vitamin D.
Additive Risk Other Vitamin D medicines/analogues Co-administration requires monitoring due to the risk of hypervitaminosis D.

Specific Restrictions

Colecalciferol use in patients with severe renal insufficiency is restricted, as the product is not metabolised normally in this population. An excipient-based contraindication exists for some capsule formulations containing Arachis (Peanut) Oil, restricting use in patients with documented allergies to peanut oil.

Mechanism of Action

Dekristol, containing cholecalciferol (vitamin D3), is a precursor molecule that requires two successive hydroxylation steps to attain biological activity. First, it is metabolized primarily in the liver by the enzyme 25-hydroxylase (CYP2R1) to form calcifediol (25-hydroxyvitamin D). This is the major circulating form. Subsequently, calcifediol is transported to the kidneys where the 1alpha-hydroxylase (CYP27B1) converts it into calcitriol (1,25-dihydroxyvitamin D), the hormonally active form.

Calcitriol acts as an agonist by binding to the high-affinity Nuclear Vitamin D Receptor (VDR), a ligand-activated transcription factor found in the nuclei of target cells, including intestinal epithelial cells and osteoblasts. Upon calcitriol binding, the VDR forms a heterodimer with the Retinoid X Receptor (RXR). This heterodimeric complex translocates to the cell's DNA and binds to specific genetic sequences known as Vitamin D Response Elements (VDREs). This VDR/RXR/VDRE interaction modulates the transcription of target genes. The downstream cascades include the increased transcription and expression of proteins involved in calcium and phosphate transport and homeostasis. System-level physiological consequences involve modulated intestinal absorption of calcium and phosphate and regulated bone mineralization.

Dosage and Administration Information

How to Use Dekristol: Administration Guidelines

Dekristol (Colecalciferol) is administered exclusively via the oral route, utilizing dosage forms such as capsules, tablets, or liquid drops. Its administration follows a protocol based on therapeutic need, typically distinguishing between a short-term correction phase and long-term maintenance.

Dosing and Schedule Structure

The usage pattern is generally divided into two phases. The loading phase, intended to correct a deficiency, may involve higher, intermittent doses, such as 50,000 IU administered weekly for approximately six to eight weeks. This is followed by a maintenance phase, where the regimen shifts to a lower, continuous dose, typically ranging from 800 IU to 2,000 IU taken daily. High-strength capsules (20,000 IU or 50,000 IU) are used for weekly or monthly intermittent dosing, while drops or lower-strength tablets facilitate the daily regimen.

Procedural Administration Specifics

Due to the fat-soluble nature of Colecalciferol, all formulations should be taken with a meal, ideally the largest meal of the day, to optimize absorption in the digestive tract. Capsules must be swallowed whole with water and must not be chewed, crushed, or split. For oral drops, the dose should be accurately measured and can be mixed with a small amount of cold or lukewarm food for immediate consumption; however, it should not be added to a full bottle of liquid or a large portion of food. In the event a dose is missed, the recommended procedure is to skip the missed dose and resume the regular schedule without taking a double dose.

Recent Clinical Evidence

Evidence for Correcting Vitamin D Deficiency and Associated Metabolic Conditions

Research primarily includes Randomized Controlled Trials (RCTs) across all age groups, aiming to address the amount of the vitamin's primary marker, 25-hydroxyvitamin D. Studies monitored changes in this marker, alongside Parathyroid Hormone (PTH) and blood calcium. Findings describe patterns observed where Colecalciferol was associated with a measured change in these metabolic markers, establishing a foundation for evaluating documented deficiency.


Research on Rickets, Osteomalacia, and Calcium Homeostasis

A significant body of evidence, including clinical studies and long-standing data, examined changes in the manifestations of these skeletal disorders in children (Rickets) and adults (Osteomalacia). The studies explored outcomes such as radiographic evidence of bone mineralization status and the change in balance of key minerals like calcium and phosphate. Findings described patterns observed in these studies related to metabolic and structural markers.


Evidence for Managing Osteoporosis and Fracture Risk

Multiple large-scale RCTs and meta-analyses monitored the incidence of hip fractures, non-vertebral fractures, and falls over several years in older adults, often with co-administered calcium. However, findings were often mixed and inconsistent. While some studies reported patterns suggesting reduced risk in institutionalized or deficient populations, other large, controlled studies reported no measurable difference compared to a placebo. Certainty remains low regarding the effect in general community-dwelling populations without known deficiency.


Areas of Research Uncertainty and Study Limitations

Research on symptomatic outcomes, such as diffuse bone pain or muscular weakness, is often based on studies where these outcomes were secondary, and findings remain limited. Long-term effects are not fully established outside of extended fracture trials. A key uncertainty is the inconsistency in findings across major studies, which highlights that study results reflect the specific populations and conditions under which they were conducted. Data for certain comorbid conditions remain insufficient.

Key Studies & References

  1. Effect of Vitamin D Supplementation on Risk of Fractures and Falls According to Dosage and Interval: A Meta-Analysis
  2. Public Assessment Report Scientific discussion Cholecalciferol Teva, 20.000 IU soft capsules (cholecalciferol) NL (Source for regulatory confirmation and established use)

Frequently Asked Questions (FAQ)

Common questions about Dekristol (FAQ)

Q: Is Dekristol a prescription drug or can I buy it over the counter?

Colecalciferol (the active ingredient in Dekristol) is available with differing regulatory status and dosage strengths across various countries. While lower doses are often available as over-the-counter (OTC) supplements, high-dose or 'mega-dose' formulations used to correct a deficiency may require a prescription.

Q: Can Dekristol be used by people who are lactose intolerant?

Official product information specifies the inactive ingredients, or excipients, used in each formulation. Although many pharmaceuticals are regarded as low-lactose, patients who have a severe intolerance may wish to confirm the specific lactose content of their preparation, as certain tablets may contain lactose.

Q: Is Dekristol safe to use during pregnancy, according to official documents?

Official regulatory documents generally permit the use of Dekristol during pregnancy, but strict limitations apply to the dosage. High doses, typically exceeding 4,000 international units (IU) per day, are officially not recommended.

Q: Does Dekristol interact with herbal supplements like St. John's Wort?

Official documents note that St. John's Wort is documented to have metabolic activity that may potentially decrease the effects of Colecalciferol. The possibility of reduced vitamin D effects may be considered when this supplement is used.

Q: Is Dekristol the same as calcifediol or calcitriol?

No, Colecalciferol (Dekristol) is the pro-hormone, or precursor molecule. After administration, it must be metabolized in the body first into calcifediol, and then into calcitriol, which is the final, hormonally active form of Vitamin D.

Q: Does Dekristol interact with calcium supplements?

Official regulatory documents caution that combining Colecalciferol with calcium supplements carries the potential for additive effects. This combination is associated with an increased risk of hypervitaminosis D (excess vitamin D) and elevated calcium levels.

Q: Are there different forms (capsules, tablets, liquid) of Dekristol available?

Yes, official product information confirms that Dekristol is available for oral administration in various forms. These typically include capsules, oral drops, and tablets to accommodate different patient needs and dosing strategies.

Q: Can children or teenagers use Dekristol?

Use is generally permitted for adolescents over 12 years of age. However, official safety restrictions state that high-dose capsules are typically not recommended for children under 12 years.

Q: Why is Dekristol prescribed for bone health?

The purpose of Colecalciferol is to maintain calcium homeostasis, or balance, in the body. The resulting active hormone stimulates the intestines to absorb necessary dietary calcium and phosphate, which are fundamental for proper bone structure and mineralization.

Q: Are there any known interactions between Dekristol and common pain relievers?

Official drug interaction information generally reports no specific interaction between Colecalciferol and common non-steroidal anti-inflammatory drugs (NSAIDs), which are widely used as pain relievers.

Q: Can taking Dekristol interfere with sleep patterns?

Official drug safety documentation does not consistently list changes to sleep patterns as a common adverse reaction. Any notable side effect would be listed in the official documents.

Q: Is it normal to feel slightly nauseous after starting Dekristol?

Nausea and vomiting are documented as potential signs associated with hypercalcaemia, which means high calcium levels in the blood. These symptoms can be caused by taking too much Colecalciferol.

Q: How long can a person safely stay on Dekristol?

Official guidelines distinguish between a time-limited correction phase for deficiency and a long-term maintenance phase for continuous use. The total duration of use is determined by the individual’s therapeutic need.

Q: What is the role of the active ingredient in Dekristol?

The active ingredient, Colecalciferol, acts as a precursor molecule to the active hormone, Calcitriol. Its primary role is to provide the critical element needed by the body to regulate calcium and phosphate homeostasis.

Q: Why do official guidelines mention potential interactions with certain heart medicines?

Official guidelines state that Colecalciferol may augment the toxicity of certain heart medicines, specifically Cardiac Glycosides (e.g., Digitalis). This concern arises from the risk of hypercalcaemia (high calcium), which can potentially induce cardiac arrhythmias.

Q: Is there a maximum time frame for using Dekristol, as described in medical literature?

The official dosing regimen distinguishes between a time-limited loading or correction phase and an ongoing, lower-dose maintenance phase. No universal maximum time frame is stated, as usage is determined by the patient's therapeutic necessity.

Q: Are there common side effects listed in official documents that people rarely talk about online?

Officially documented common side effects include gastrointestinal discomfort, such as pain and nausea, as well as headache. These symptoms are associated with the potential development of high calcium levels.

Q: How is the need for Dekristol usually confirmed by a doctor?

The initiation and continuation of Dekristol treatment are typically determined by monitoring key metabolic markers. The need is primarily confirmed by assessing the level of the primary marker, 25-hydroxyvitamin D, alongside blood calcium levels.

Q: Is Dekristol a steroid?

The active ingredient, Colecalciferol, is defined as a pro-hormone and is structurally classified as a secosteroid. This means it is chemically related to other steroid-like hormones in the body.

Q: Does Dekristol contain any common allergens like gluten or soy?

Safety restrictions mandate screening for known excipients like arachis oil (peanut oil). The specific product labeling contains the complete list of excipients, and most pharmaceuticals are developed to be gluten-free.

Q: What information is available about Dekristol’s safety profile for people with liver issues?

Official information indicates that Colecalciferol undergoes its initial metabolic activation primarily in the liver. Therefore, any pre-existing hepatic impairment (liver issues) may affect the drug's metabolism and its expected therapeutic activity.

Q: What is the main active ingredient, and what type of drug classification does it fall under?

The main active ingredient is Colecalciferol (Vitamin D3). It is classified by regulatory agencies as a fat-soluble vitamin, a nutritional supplement, and belongs to the pharmacological class of Vitamin D analogs.

Q: Are the listed contraindications for Dekristol permanent or temporary?

Contraindications for use can be both temporary and permanent. Conditions such as high calcium levels (hypercalcaemia) can be temporary. However, a known hypersensitivity or allergy to the active substance or its excipients is considered a permanent restriction.

Q: Is there a link between Dekristol use and kidney stones mentioned in official warnings?

Official drug documentation lists Nephrolithiasis (the medical term for kidney stones) as an absolute contraindication for use. This classification restricts the use of the medication in individuals with this condition.

Q: Can I take Dekristol if I have a pre-existing gastrointestinal condition?

Official information notes that certain drugs and pre-existing conditions that impair fat absorption are documented to interfere with the uptake of the fat-soluble Colecalciferol. This interference can reduce the intended therapeutic effect.

Q: Has Dekristol been studied in different ethnic groups?

Official documents often list certain populations, such as 'Dark skinned individuals,' as being at high risk for vitamin D deficiency. Such listings indicate a necessity for specific monitoring and, potentially, varied dosing protocols in these groups.

Q: Why is Dekristol often mentioned alongside osteoporosis treatment?

Official research and the drug's regulatory indications include the use of Colecalciferol as an adjunct to specific therapy for osteoporosis. This use is based on evidence related to its ability to maintain bone health.

Q: Is Dekristol available in generic form?

Yes, Colecalciferol, which is the active pharmaceutical ingredient in Dekristol, is widely available from various manufacturers as a generic medication.

Q: Why does the packaging for Dekristol often mention kidney function?

The packaging mentions kidney function because the kidneys are the final site where Colecalciferol is metabolically converted into its fully active hormone. Consequently, severe renal impairment is listed as a contraindication for use.

Q: Is it okay to take Dekristol if I am already spending time in the sun?

Colecalciferol is naturally produced in the skin upon exposure to sunlight. However, supplementation with Dekristol is generally intended to treat or prevent deficiency in individuals whose natural production is insufficient, such as those with limited sun exposure.

How should Dekristol be stored and disposed of?

Dekristol (colecalciferol) must be stored and disposed of according to strict regulatory requirements to maintain its stability and ensure environmental protection.

Storage Conditions

Requirement Official Statement
Temperature Store below 25 C or as specified on the package label.
Protection Keep in the original package to protect from light and moisture.
Child Safety Keep out of the sight and reach of children.
Stability The unopened product has an established shelf life of 36 months when stored correctly.

Disposal Instructions

Disposal must adhere to pharmaceutical waste procedures. Patients should not dispose of medicines via wastewater or household waste. Any unused or expired Dekristol must be disposed of in accordance with local requirements, typically through a pharmacy take-back scheme or an authorized collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dekristol found in:

A-Z Index: